Thermostable Vaccines Based On Ether Lipids And Native Viral Envelope Proteins
AssigneeBatavia Biosciences Inc.
InventorsDavid Foster, Menzo Jans Emco Havenga
Life of this patent
Estimating the term…
Abstract
A platform enabling the manufacture of thermostable vaccines by incorporating recombinantly expressed, viral envelope proteins in their native conformation into ether glycerophospholipid nanodisc structures that simulate the natural environment of the envelope proteins. The ether glycerophospholipids include ether-linked hydrophobic side chains, and are derived from or modeled after those found in thermophile bacteria, which increase thermostability, thereby significantly enhancing the vaccine's potency, enabling the production of highly multivalent vaccines incorporating multiple variants of the viral antigen, and improving stability and shelf-life.
Claims20
A thermostable vaccine carrier, comprising a bilayer comprising one or more ether glycerophospholipids and one or more membrane scaffold proteins self-assembled into a nanodisc, and a microbial protein antigen embedded into the nanodisc.
A process for producing substantially pure Ebola GP protein, comprising transfecting Ebola VP40 protein-expressing stable cells with a gene encoding the Ebola GP protein, isolating virus-like particles comprising the Ebola VP40 protein and Ebola GP protein produced from the transfected cells, separating the GP protein from the VP40 protein, and purifying the separated GP protein.
Mammalian cells stably transformed with a recombinant gene encoding the Ebola virus VP40 protein.
Dependencies are inferred from the claim text.